I think it warrants making a new publication here, 
BIIB has flashed a buy signal with tremendously good reward to risk, as it can resume the long term trend that can take it over $1600-2600 over time. Phase 3 clinical trials have gone really well for their Alzheimer's treatment 'Aduhelm', putting it in line with results obtained by 
LLY's drug 'Donanemab'. I was long LLY and have been trading in and out of BIIB trying to time the end of the long slide since the FDA approval news came out. I think the time is now, to get in and sit tight. I've banked my LLY exposure, but both companies will likely do well with their Alzheimer's treatments going forward and have solid trends, but the reward to risk favors BIIB, so I'm only long Biogen currently.
Best of luck!
Cheers,
Ivan.
BIIB has flashed a buy signal with tremendously good reward to risk, as it can resume the long term trend that can take it over $1600-2600 over time. Phase 3 clinical trials have gone really well for their Alzheimer's treatment 'Aduhelm', putting it in line with results obtained by LLY's drug 'Donanemab'. I was long LLY and have been trading in and out of BIIB trying to time the end of the long slide since the FDA approval news came out. I think the time is now, to get in and sit tight. I've banked my LLY exposure, but both companies will likely do well with their Alzheimer's treatments going forward and have solid trends, but the reward to risk favors BIIB, so I'm only long Biogen currently.Best of luck!
Cheers,
Ivan.
Not
İşlem kapandı: durdurma seviyesi
Public, timestamped track record. Free month of the desk: ivanlabrie.netlify.app
İlgili yayınlar
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, alım satım veya diğer türden tavsiye veya öneriler anlamına gelmez ve teşkil etmez. Kullanım Koşulları bölümünde daha fazlasını okuyun.
Public, timestamped track record. Free month of the desk: ivanlabrie.netlify.app
İlgili yayınlar
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, alım satım veya diğer türden tavsiye veya öneriler anlamına gelmez ve teşkil etmez. Kullanım Koşulları bölümünde daha fazlasını okuyun.